MedKoo product information:

 Doxorubicin Hydrochloride

Doxorubicin hydrochloride is the hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

History

The history of doxorubicin can be traced back to the 1950s, when an Italian research company, Farmitalia Research Laboratories, began an organized effort to find anticancer compounds from soil-based microbes. A soil sample was isolated from the area surrounding the Castel del Monte, a 13th century castle. A new strain of Streptomyces peucetius which produced a red pigment was isolated, and an antibiotic was produced from this bacterium that was found to have good activity against murine tumors. Since a group of French researchers discovered the same compound at about the same time, the two teams named the compound daunorubicin, combining the name Dauni, a pre-Roman tribe that occupied the area of Italy where the compound was isolated, with the French word for ruby, rubis, describing the color.Clinical trials began in the 1960s, and the drug saw success in treating acute leukemia and lymphoma. However, by 1967, it was recognized that daunorubicin could produce fatal cardiac toxicity. Researchers at Farmitalia soon discovered that changes in biological activity could be made by minor changes in the structure of the compound. A strain of Streptomyces was mutated using N-nitroso-N-methyl urethane and this new strain produced a different, red-colored antibiotic. They named this new compound Adriamycin, after the Adriatic Sea, and the name was later changed to doxorubicin to conform to the established naming convention. Doxorubicin showed better activity than daunorubicin against murine tumors, and especially solid tumors. It also showed a higher therapeutic index, yet the cardiotoxicity remained. Doxorubicin and daunorubicin together can be thought of as prototype compounds for the anthracyclines. Subsequent research by many investigators throughout the world has led to many other anthracycline antibiotics, or analogs, and it is now estimated that there are over 2,000 known analogs of doxorubicin. By 1991, 553 of them had been evaluated in the screening program at the National Cancer Institute (NCI). see: http://en.wikipedia.org/wiki/Doxorubicin.

DRUG DESCRIPTION

Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin consists of a naphthacenequinone nucleus linked through a glycosidic bond at ring atom 7 to an amino sugar, daunosamine. Chemically, doxorubicin hydrochloride is: 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxylacetyl)-1-methoxy-, hydrochloride (8S-cis)-. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix. The anthracycline ring is lipophilic, but the saturated end of the ring system contains abundant hydroxyl groups adjacent to the amino sugar, producing a hydrophilic center. The molecule is amphoteric, containing acidic functions in the ring phenolic groups and a basic function in the sugar amino group. It binds to cell membranes as well as plasma proteins. Doxorubicin Hydrochloride for Injection, USP, is a sterile red-orange lyophilized powder. Doxorubicin Hydrochloride Injection, USP, is a sterile parenteral, isotonic solution.

CLINICAL PHARMACOLOGY

The cytotoxic effect of doxorubicin on malignant cells and its toxic effects on various organs are thought to be related to nucleotide base intercalation and cell membrane lipid binding activities of doxorubicin. Intercalation inhibits nucleotide replication and action of DNA and RNA polymerases. The interaction of doxorubicin with topoisomerase II to form DNA-cleavable complexes appears to be an important mechanism of doxorubicin cytocidal activity. Doxorubicin cellular membrane binding may affect a variety of cellular functions. Enzymatic electron reduction of doxorubicin by a variety of oxidases, reductases and dehydrogenases generates highly reactive species including the hydroxyl free radical OH•. Free radical formation has been implicated in doxorubicin cardiotoxicity by means of Cu (II) and Fe (III) reduction at the cellular level. Cells treated with doxorubicin have been shown to manifest the characteristic morphologic changes associated with apoptosis or programmed cell death. Doxorubicin-induced apoptosis may be an integral component of the cellular mechanism of action relating to therapeutic effects, toxicities, or both. Animal studies have shown activity in a spectrum of experimental tumors, immunosuppression, carcinogenic properties in rodents, induction of a variety of toxic effects, including delayed and progressive cardiac toxicity, myelosuppression in all species and atrophy to testes in rats and dogs.

 1: Liu YY, Gupta V, Patwardhan GA, Bhinge K, Zhao Y, Bao J, Mehendale H, Cabot MC, Li YT, Jazwinski SM. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. Mol Cancer. 2010 Jun 11;9(1):145. [Epub ahead of print] PubMed PMID: 20540746.

2: Zaremba T, Thomas H, Cole M, Plummer ER, Curtin NJ. Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials. Cancer Chemother Pharmacol. 2010 May 21. [Epub ahead of print] PubMed PMID: 20490796.

3: Angelini A, Di Ilio C, Castellani ML, Conti P, Cuccurullo F. Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy. J Biol Regul Homeost Agents. 2010 Apr-Jun;24(2):197-205. PubMed PMID: 20487633.

4: Hawtin RE, Stockett DE, Byl JA, McDowell RS, Nguyen T, Arkin MR, Conroy A, Yang W, Osheroff N, Fox JA. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS One. 2010 Apr 15;5(4):e10186. PubMed PMID: 20419121; PubMed Central PMCID: PMC2855444.

5: Hrebackova J, Hrabeta J, Eckschlager T. Valproic Acid in the complex therapy of malignant tumors. Curr Drug Targets. 2010 Mar;11(3):361-79. PubMed PMID: 20214599.

6: Li R, Wu R, Zhao L, Wu M, Yang L, Zou H. P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. ACS Nano. 2010 Mar 23;4(3):1399-408. PubMed PMID: 20148593.

7: Lünenbürger H, Lanvers-Kaminsky C, Lechtape B, Frühwald MC. Systematic analysis of the antiproliferative effects of novel and standard anticancer agents in rhabdoid tumor cell lines. Anticancer Drugs. 2010 Jun;21(5):514-22. PubMed PMID: 20147838.

8: Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, García-Echeverría C, Mercuri M, Picci P, Scotlandi K. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res. 2010 Jan 15;16(2):530-40. Epub 2010 Jan 12. PubMed PMID: 20068094.

9: Bisht S, Maitra A. Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 Jul;1(4):415-25. Review. PubMed PMID: 20049807.

10: Duncan R, Vicent MJ. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. Adv Drug Deliv Rev. 2010 Feb 17;62(2):272-82. Epub 2009 Dec 11. PubMed PMID: 20005271.

11: Lorusso D, Mainenti S, Pietragalla A, Ferrandina G, Foco G, Masciullo V, Scambia G. Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity. Expert Opin Investig Drugs. 2009 Dec;18(12):1939-46. PubMed PMID: 19938904.

12: Duncan R. Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt. Adv Drug Deliv Rev. 2009 Nov 12;61(13):1131-48. Epub 2009 Aug 20. Review. PubMed PMID: 19699249.

13: Msaouel P, Galanis E, Koutsilieris M. Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology. Expert Opin Investig Drugs. 2009 Sep;18(9):1297-316. Review. PubMed PMID: 19678799.

14: Bhat UG, Halasi M, Gartel AL. FoxM1 is a general target for proteasome inhibitors. PLoS One. 2009 Aug 12;4(8):e6593. PubMed PMID: 19672316; PubMed Central PMCID: PMC2721658.

15: Xie Y, Bagby TR, Cohen MS, Forrest ML. Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies. Expert Opin Drug Deliv. 2009 Aug;6(8):785-92. Review. PubMed PMID: 19563270.

16: Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 2009 Apr;100(4):572-9. Review. PubMed PMID: 19462526.

17: Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G, Zhu QS, Bornmann WG, McConkey DJ, Pollock RE, Lev DC. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res. 2009 May 15;15(10):3472-83. Epub 2009 May 5. PubMed PMID: 19417021.

18: Olofsson MH, Cummings J, Fayad W, Brnjic S, Herrmann R, Berndtsson M, Hodgkinson C, Dean E, Odedra R, Wilkinson RW, Mundt KE, Busk M, Dive C, Linder S. Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker. Cancer Biomark. 2009;5(3):117-25. PubMed PMID: 19407366.

19: Simůnek T, Stérba M, Popelová O, Adamcová M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep. 2009 Jan-Feb;61(1):154-71. Review. PubMed PMID: 19307704.

20: Gligorov J, Lotz JP. Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2008 Dec;112 Suppl 1:53-66. Epub 2008 Dec 20. PubMed PMID: 19101794.

21: Benhadji KA, Serova M, Ghoul A, Cvitkovic E, Le Tourneau C, Ogbourne SM, Lokiec F, Calvo F, Hammel P, Faivre S, Raymond E. Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells. Br J Cancer. 2008 Dec 2;99(11):1808-15. PubMed PMID: 19034280; PubMed Central PMCID: PMC2600681.

22: Novotna R, Wsol V, Xiong G, Maser E. Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett. 2008 Sep;181(1):1-6. Epub 2008 Jun 21. PubMed PMID: 18616992.

23: Lau D, Johl J, Huynh M, Davies A, Tanaka M, Lara P, Gandara D. Population-based phase I trial of irinotecan and epirubicin. Am J Clin Oncol. 2008 Jun;31(3):226-30. PubMed PMID: 18525299.

24: Efferth T, Konkimalla VB, Wang YF, Sauerbrey A, Meinhardt S, Zintl F, Mattern J, Volm M. Prediction of broad spectrum resistance of tumors towards anticancer drugs. Clin Cancer Res. 2008 Apr 15;14(8):2405-12. PubMed PMID: 18413831.

25: Ballatori E, Roila F, Ruggeri B, De Angelis V, Porzio G, Marchetti P; Italian Group for Antiemetic Research. Inappropriate doses of chemotherapy in Italian breast cancer patients enrolled in clinical trials. Tumori. 2007 Nov-Dec;93(6):540-3. PubMed PMID: 18338486.

26: Kouloulias VE, Koukourakis GV, Petridis AK, Kouvaris I, Gouliamos AD. The efficacy of caelyx and hyperthermia for anticancer treatment. Recent Pat Anticancer Drug Discov. 2007 Nov;2(3):246-50. Review. PubMed PMID: 18221068.

27: Colado E, Alvarez-Fernández S, Maiso P, Martín-Sánchez J, Vidriales MB, Garayoa M, Ocio EM, Montero JC, Pandiella A, San Miguel JF. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. Haematologica. 2008 Jan;93(1):57-66. PubMed PMID: 18166786.

28: Herst PM, Petersen T, Jerram P, Baty J, Berridge MV. The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells. Biochem Pharmacol. 2007 Dec 3;74(11):1587-95. Epub 2007 Aug 19. PubMed PMID: 17904534.

29: Schöffski P, Wolter P, Clement P, Sciot R, De Wever I, Wozniak A, Stefan C, Dumez H. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma. Future Oncol. 2007 Aug;3(4):381-92. Review. PubMed PMID: 17661712.

30: Liang CH, Shiu LY, Chang LC, Sheu HM, Kuo KW. Solamargine upregulation of Fas, downregulation of HER2, and enhancement of cytotoxicity using epirubicin in NSCLC cells. Mol Nutr Food Res. 2007 Aug;51(8):999-1005. PubMed PMID: 17639997.

31: Kratz F, Abu Ajaj K, Warnecke A. Anticancer carrier-linked prodrugs in clinical trials. Expert Opin Investig Drugs. 2007 Jul;16(7):1037-58. Review. PubMed PMID: 17594188.

32: Sieghart W, Fuereder T, Schmid K, Cejka D, Werzowa J, Wrba F, Wang X, Gruber D, Rasoul-Rockenschaub S, Peck-Radosavljevic M, Wacheck V. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation. 2007 Feb 27;83(4):425-32. PubMed PMID: 17318075.

33: Duncan R. Designing polymer conjugates as lysosomotropic nanomedicines. Biochem Soc Trans. 2007 Feb;35(Pt 1):56-60. Review. PubMed PMID: 17233601.

34: Vogel C, Hager C, Bastians H. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res. 2007 Jan 1;67(1):339-45. PubMed PMID: 17210716.

35: Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007 Jan-Feb;30(1):6-25. Review. PubMed PMID: 17103105.

36: Robert J. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls. Cell Biol Toxicol. 2007 Jan;23(1):27-37. Epub 2006 Oct 13. Review. PubMed PMID: 17041747.

37: Menna P, Minotti G, Salvatorelli E. In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity. Cell Biol Toxicol. 2007 Jan;23(1):49-62. Epub 2006 Oct 9. Review. PubMed PMID: 17031515.

38: Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766. Drugs R D. 2006;7(5):317-28. Review. PubMed PMID: 16922593.

39: Bridges EM, Bibby MC, Burchill SA. The hollow fiber assay for drug responsiveness in the Ewing's sarcoma family of tumors. J Pediatr. 2006 Jul;149(1):103-11. PubMed PMID: 16860137.

40: Hasinoff BB. Dexrazoxane use in the prevention of anthracycline extravasation injury. Future Oncol. 2006 Feb;2(1):15-20. Review. PubMed PMID: 16556068.

41: Haag R, Kratz F. Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl. 2006 Feb 13;45(8):1198-215. Review. PubMed PMID: 16444775.

42: Dubey AK, Shankar PR, Upadhyaya D, Deshpande VY. Ginkgo biloba--an appraisal. Kathmandu Univ Med J (KUMJ). 2004 Jul-Sep;2(3):225-9. Review. PubMed PMID: 16400219.

43: Vicent MJ, Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol. 2006 Jan;24(1):39-47. Epub 2005 Nov 22. Review. PubMed PMID: 16307811.

44: Costanzi J, Sidransky D, Navon A, Goldsweig H. Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase. Cancer Invest. 2005;23(7):643-50. Review. PubMed PMID: 16305992.

45: Saeki T, Tsuruo T, Sato W, Nishikawsa K. Drug resistance in chemotherapy for breast cancer. Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:84-9. PubMed PMID: 16273361.

46: Glasmacher A, von Lilienfeld-Toal M. The current status of thalidomide in the management of multiple myeloma. Acta Haematol. 2005;114 Suppl 1:3-7. Review. PubMed PMID: 16166765.

47: Duncan R, Vicent MJ, Greco F, Nicholson RI. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S189-99. Review. PubMed PMID: 16113096.

48: Sachdeva MS. Drug targeting systems for cancer chemotherapy. Expert Opin Investig Drugs. 1998 Nov;7(11):1849-64. PubMed PMID: 15991934.

49: Kumar CC, Madison V. Drugs targeted against protein kinases. Expert Opin Emerg Drugs. 2001 Oct;6(2):303-15. PubMed PMID: 15989528.

50: Ozdemir FA, Anilanmert B, Pekin M. Spectrophotometric investigation of the chemical compatibility of the anticancer drugs irinotecan-HCl and epirubicin-HCl in the same infusion solution. Cancer Chemother Pharmacol. 2005 Nov;56(5):529-34. Epub 2005 Jun 10. PubMed PMID: 15947932.

51: Shanks RH, Rizzieri DA, Flowers JL, Colvin OM, Adams DJ. Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia. Clin Cancer Res. 2005 Jun 1;11(11):4225-33. PubMed PMID: 15930361.

52: Gligorov J, Debourdeau P, Arsovski O, Lotz JP. [Cardiac prevention: the oncologic point of view]. Bull Cancer. 2004 Nov 1;91 Suppl 3:192-200. Review. French. PubMed PMID: 15899627.

53: Hofland KF, Thougaard AV, Sehested M, Jensen PB. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. Clin Cancer Res. 2005 May 15;11(10):3915-24. PubMed PMID: 15897593.

54: Zhu K, Gerbino E, Beaupre DM, Mackley PA, Muro-Cacho C, Beam C, Hamilton AD, Lichtenheld MG, Kerr WG, Dalton W, Alsina M, Sebti SM. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood. 2005 Jun 15;105(12):4759-66. Epub 2005 Feb 22. PubMed PMID: 15728126; PubMed Central PMCID: PMC1895008.

55: Di Paolo A. Liposomal anticancer therapy: pharmacokinetic and clinical aspects. J Chemother. 2004 Nov;16 Suppl 4:90-3. Review. PubMed PMID: 15688620.

56: Chanan-Khan AA. Bcl-2 antisense therapy in multiple myeloma. Oncology (Williston Park). 2004 Nov;18(13 Suppl 10):21-4. Review. PubMed PMID: 15651173.

57: Pestalozzi BC, Knuth A. [New antibodies in cancer treatment]. Praxis (Bern 1994). 2004 Sep 22;93(39):1589-92. Review. German. PubMed PMID: 15500243.

58: Peer D, Dekel Y, Melikhov D, Margalit R. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res. 2004 Oct 15;64(20):7562-9. PubMed PMID: 15492283.

59: Di Nicolantonio F, Knight LA, Glaysher S, Whitehouse PA, Mercer SJ, Sharma S, Mills L, Prin A, Johnson P, Charlton PA, Norris D, Cree IA. Ex vivo reversal of chemoresistance by tariquidar (XR9576). Anticancer Drugs. 2004 Oct;15(9):861-9. PubMed PMID: 15457126.

60: Yuan S, Zhang X, Lu L, Xu C, Yang W, Ding J. Anticancer activity of methoxymorpholinyl doxorubicin (PNU 152243) on human hepatocellular carcinoma. Anticancer Drugs. 2004 Jul;15(6):641-6. PubMed PMID: 15205610.

61: Ardavanis A, Tryfonopoulos D, Yiotis I, Gerasimidis G, Baziotis N, Rigatos G. Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs. 2004 Jul;15(6):581-5. PubMed PMID: 15205600.

62: Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, Brampton M, Halbert G, Ranson M. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer. 2004 Jun 1;90(11):2085-91. PubMed PMID: 15150584; PubMed Central PMCID: PMC2409484.

63: Reynolds CP, Maurer BJ, Kolesnick RN. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett. 2004 Apr 8;206(2):169-80. Review. PubMed PMID: 15013522.

64: Janmaat ML, Giaccone G. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today (Barc). 2003;39 Suppl C:61-80. Review. PubMed PMID: 14988746.

65: Hu Y, Krishan A, Nie W, Sridhar KS, Mayer LD, Bally M. Synergistic cytotoxicity of pyrazoloacridine with doxorubicin, etoposide, and topotecan in drug-resistant tumor cells. Clin Cancer Res. 2004 Feb 1;10(3):1160-9. PubMed PMID: 14871996.

66: Vermorken JB. The role of anthracyclines in second-line therapy of ovarian cancer. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:178-84. Review. PubMed PMID: 14656277.

67: D'Incalci M, Jimeno J. Preclinical and clinical results with the natural marine product ET-743. Expert Opin Investig Drugs. 2003 Nov;12(11):1843-53. Review. PubMed PMID: 14585059.

68: Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716. Drugs R D. 2003;4(6):352-8. Review. PubMed PMID: 14584964.

69: Ríhová B, Kubácková K. Clinical implications of N-(2-hydroxypropyl)methacrylamide copolymers. Curr Pharm Biotechnol. 2003 Oct;4(5):311-22. Review. PubMed PMID: 14529421.

70: Kabanov AV, Batrakova EV, Alakhov VY. An essential relationship between ATP depletion and chemosensitizing activity of Pluronic block copolymers. J Control Release. 2003 Aug 28;91(1-2):75-83. Review. PubMed PMID: 12932639.

71: Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori. 2003 May-Jun;89(3):237-49. Review. PubMed PMID: 12908776.

72: Peterson CM, Shiah JG, Sun Y, Kopecková P, Minko T, Straight RC, Kopecek J. HPMA copolymer delivery of chemotherapy and photodynamic therapy in ovarian cancer. Adv Exp Med Biol. 2003;519:101-23. Review. PubMed PMID: 12675211.

73: Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol. 2002 Aug;16(4):253-62. Review. PubMed PMID: 12570013.

74: Sharpe M, Easthope SE, Keating GM, Lamb HM. Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. Drugs. 2002;62(14):2089-126. Review. PubMed PMID: 12269857.

75: Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev. 2002 Sep 13;54(5):759-79. Review. PubMed PMID: 12204601.

76: Frost BM, Lönnerholm G, Nygren P, Larsson R, Lindhagen E. In vitro activity of the novel cytotoxic agent CHS 828 in childhood acute leukemia. Anticancer Drugs. 2002 Aug;13(7):735-42. PubMed PMID: 12187330.

77: Albella B, Faircloth G, López-Lázaro L, Guzmán C, Jimeno J, Bueren JA. In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results. Eur J Cancer. 2002 Jul;38(10):1395-404. PubMed PMID: 12091072.

78: Kindler HL. Malignant pleural mesothelioma. Curr Treat Options Oncol. 2000 Oct;1(4):313-26. Review. PubMed PMID: 12057157.

79: Collery P, Keppler B, Madoulet C, Desoize B. Gallium in cancer treatment. Crit Rev Oncol Hematol. 2002 Jun;42(3):283-96. Review. PubMed PMID: 12050020.

80: Carrasco C, Vezin H, Wilson WD, Ren J, Chaires JB, Bailly C. DNA binding properties of the indolocarbazole antitumor drug NB-506. Anticancer Drug Des. 2001 Apr-Jun;16(2-3):99-107. PubMed PMID: 11962518.

81: Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, Doran J, Young AM, Burtles S, Kerr DJ; Cancer Research Campaign Phase I/II Clinical Trials committee. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol. 2002 Mar 15;20(6):1668-76. PubMed PMID: 11896118.

82: Cutts SM, Rephaeli A, Nudelman A, Hmelnitsky I, Phillips DR. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res. 2001 Nov 15;61(22):8194-202. PubMed PMID: 11719450.

83: da Rocha AB, Lopes RM, Schwartsmann G. Natural products in anticancer therapy. Curr Opin Pharmacol. 2001 Aug;1(4):364-9. Review. PubMed PMID: 11710734.

84: Kruczynski A, Hill BT. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol. 2001 Nov;40(2):159-73. Review. PubMed PMID: 11682323.

85: Smith V, Raynaud F, Workman P, Kelland LR. Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol. Mol Pharmacol. 2001 Nov;60(5):885-93. PubMed PMID: 11641415.

86: Kim R, Osaki A, Toge T. A pitfall in the survival benefit of adjuvant chemotherapy for node- and hormone receptor-positive patients with breast cancer: the paradoxical role of Bcl-2 oncoprotein (review). Int J Oncol. 2001 Nov;19(5):1075-80. Review. PubMed PMID: 11605012.

87: Dowlati A, Haaga J, Remick SC, Spiro TP, Gerson SL, Liu L, Berger SJ, Berger NA, Willson JK. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res. 2001 Oct;7(10):2971-6. PubMed PMID: 11595684.

88: Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC. Tumor targeting using anti-her2 immunoliposomes. J Control Release. 2001 Jul 6;74(1-3):95-113. PubMed PMID: 11489487.

89: Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, Furukawa Y. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood. 2001 Apr 1;97(7):1999-2007. PubMed PMID: 11264164.

90: Gu B, Wu D, Li M, Lü H. Potentiation of docetaxel antitumor activity by batimastat against mouse forestomach carcinoma. J Environ Pathol Toxicol Oncol. 2000;19(4):375-82. PubMed PMID: 11213020.

91: Dantzig AH, Law KL, Cao J, Starling JJ. Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. Curr Med Chem. 2001 Jan;8(1):39-50. Review. PubMed PMID: 11172691.

92: Zagozdzon R, Golab J. Immunomodulation by anticancer chemotherapy: more is not always better (review). Int J Oncol. 2001 Feb;18(2):417-24. Review. PubMed PMID: 11172612.

93: Trimble EL. Innovative therapies for advanced ovarian cancer. Semin Oncol. 2000 Jun;27(3 Suppl 7):24-30. Review. PubMed PMID: 10952123.

94: Baba H, Kohnoe S, Endo K, Ikeda Y, Toh Y, Nakashima H, Okamura T. [State of the treatment for gastrointestinal cancer]. Gan To Kagaku Ryoho. 2000 Jul;27(8):1233-46. Review. Japanese. PubMed PMID: 10945022.

95: Vadgama JV, Wu Y, Shen D, Hsia S, Block J. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells. Anticancer Res. 2000 May-Jun;20(3A):1391-414. PubMed PMID: 10928049.

96: Liao WC, Wu FY, Wu CW. Binary/ternary combined effects of vitamin K3 with other antitumor agents in nasopharyngeal carcinoma CG1 cells. Int J Oncol. 2000 Aug;17(2):323-8. PubMed PMID: 10891542.

97: Finlay GJ, Baguley BC. Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs. Cancer Chemother Pharmacol. 2000;45(5):417-22. PubMed PMID: 10803926.

98: Marshall RF, Arthaud LE, MacDonald JR. Evaluation of antidotes for extravasation injury produced by 6-hydroxymethylacylfulvene (MGI 114), a novel cytotoxic antitumor agent, in an intradermal toxicity model in rats. Cancer Chemother Pharmacol. 2000;45(5):397-401. PubMed PMID: 10803923.

99: Supko JG, Nair RV, Seiden MV, Lu H. Adaptation of solid phase extraction to an automated column switching method for online sample cleanup as the basis of a facile and sensitive high-performance liquid chromatographic assay for paclitaxel in human plasma. J Pharm Biomed Anal. 1999 Dec;21(5):1025-36. PubMed PMID: 10703971.

100: Armand JP, Seymour L, Evans TR. Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines: preliminary results of phase I clinical trials. Eur J Cancer. 1999 Mar;35 Suppl 1:S14-8. PubMed PMID: 10645209.

101: Hidalgo M, Izbicka E, Eckhardt SG, MacDonald JR, Cerna C, Gomez L, Rowinsky EK, Weitman SD, Von Hoff DD. Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units. Anticancer Drugs. 1999 Oct;10(9):837-44. PubMed PMID: 10587294.

102: Hoffmann J, Schmidt-Peter P, Hänsch W, Naundorf H, Bunge A, Becker M, Fichtner I. Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas. Clin Cancer Res. 1999 Aug;5(8):2198-204. PubMed PMID: 10473106.

103: Gurnani M, Lipari P, Dell J, Shi B, Nielsen LL. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother Pharmacol. 1999;44(2):143-51. PubMed PMID: 10412949.

104: Ferrante K, Winograd B, Canetta R. Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol. 1999;43 Suppl:S61-8. Review. PubMed PMID: 10357561.

105: Robert J. Multidrug resistance in oncology: diagnostic and therapeutic approaches. Eur J Clin Invest. 1999 Jun;29(6):536-45. Review. PubMed PMID: 10354216.

106: Ogawa M. Novel anticancer drugs in Japan. J Cancer Res Clin Oncol. 1999;125(3-4):134-40. Review. PubMed PMID: 10235466.

107: Garner AP, Paine MJ, Rodriguez-Crespo I, Chinje EC, Ortiz De Montellano P, Stratford IJ, Tew DG, Wolf CR. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Res. 1999 Apr 15;59(8):1929-34. PubMed PMID: 10213502.

108: Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res. 1999 Apr;5(4):909-16. PubMed PMID: 10213228.

109: Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res. 1997 Dec;3(12 Pt 2):2703-7. Review. PubMed PMID: 10068277.

110: Gianni L, Capri G, Valagussa P, Bonadonna G. Putting taxanes to work in operable breast cancer: a search for selective indications from empirical studies. Recent Results Cancer Res. 1998;152:314-22. Review. PubMed PMID: 9928568.

111: Chvetzoff G, Bonnotte B, Chauffert B. [Anticancer chemotherapy. Prevention of toxicity]. Presse Med. 1998 Dec 12;27(39):2106-12. Review. French. PubMed PMID: 9893704.

112: Andoh T. Bis(2,6-dioxopiperazines), catalytic inhibitors of DNA topoisomerase II, as molecular probes, cardioprotectors and antitumor drugs. Biochimie. 1998 Mar;80(3):235-46. Review. PubMed PMID: 9615863.

113: Arcamone FM. From the pigments of the actinomycetes to third generation antitumor anthracyclines. Biochimie. 1998 Mar;80(3):201-6. Review. PubMed PMID: 9615860.

114: Raymond E, Lawrence R, Izbicka E, Faivre S, Von Hoff DD. Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res. 1998 Apr;4(4):1021-9. PubMed PMID: 9563898.

115: Arcamone F, Animati F, Capranico G, Lombardi P, Pratesi G, Manzini S, Supino R, Zunino F. New developments in antitumor anthracyclines. Pharmacol Ther. 1997 Oct-Dec;76(1-3):117-24. Review. PubMed PMID: 9535173.

116: Duncan R, Coatsworth JK, Burtles S. Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1). Hum Exp Toxicol. 1998 Feb;17(2):93-104. PubMed PMID: 9506260.

117: Covelli A. [SDZ PSC 833: a novel modulator of MDR]. Tumori. 1997 Sep-Oct;83(5 Suppl):S21-4. Review. Italian. PubMed PMID: 9446255.

118: Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 1997 Oct;11(12):931-6. Review. PubMed PMID: 9337145.

119: Khayat D, Antoine E. Docetaxel in combination chemotherapy for metastatic breast cancer. Semin Oncol. 1997 Aug;24(4 Suppl 13):S13-19-S13-26. Review. PubMed PMID: 9335513.

120: Watanabe T, Iwasaki M, Todaka T, Morikawa H, Ohtawa M. Effect of SDZ PSC 833 ([3'-keto-Bmt1]-[Val2]-cyclosporin) on serum protein binding and distribution to blood cells of doxorubicin, vincristine and etoposide in vitro. Anticancer Drugs. 1997 Apr;8(4):400-4. PubMed PMID: 9180396.

121: Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol. 1997;40 Suppl:S13-9. Review. PubMed PMID: 9272128.

122: Caponigro F, French RC, Kaye SB. Protein kinase C: a worthwhile target for anticancer drugs? Anticancer Drugs. 1997 Jan;8(1):26-33. Review. PubMed PMID: 9147607.

123: Lévi F. [Chronopharmacology and chronotherapy of cancers]. Pathol Biol (Paris). 1996 Sep;44(7):631-44. Review. French. PubMed PMID: 8977920.

124: Zervas K, Pouli A, Perifanis V, Papanastasiou K, Chatziyianni M, Mitsouli C, Maniatis A. Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group. Eur J Haematol. 1996 Aug;57(2):142-8. PubMed PMID: 8856091.

125: Hellmann K. Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care. Support Care Cancer. 1996 Jul;4(4):305-7. Review. PubMed PMID: 8829310.

126: Bissery MC, Vrignaud P, Lavelle F, Chabot GG. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs. 1996 Jun;7(4):437-60. PubMed PMID: 8826613.

127: Tsai CM, Levitzki A, Wu LH, Chang KT, Cheng CC, Gazit A, Perng RP. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res. 1996 Mar 1;56(5):1068-74. PubMed PMID: 8640763.

128: Capri G, Tarenzi E, Fulfaro F, Gianni L. The role of taxanes in the treatment of breast cancer. Semin Oncol. 1996 Feb;23(1 Suppl 2):68-75. Review. PubMed PMID: 8614849.

129: Verweij J. New promising anticancer agents in development: what comes next? Cancer Chemother Pharmacol. 1996;38 Suppl:S3-10. Review. PubMed PMID: 8765408.

130: van Oosterom AT. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer. Semin Oncol. 1995 Dec;22(6 Suppl 13):22-8. PubMed PMID: 8604449.

131: Berger I, Su L, Spitzner JR, Kang C, Burke TG, Rich A. Molecular structure of the halogenated anti-cancer drug iododoxorubicin complexed with d(TGTACA) and d(CGATCG). Nucleic Acids Res. 1995 Nov 11;23(21):4488-94. PubMed PMID: 7501474; PubMed Central PMCID: PMC307408.

132: Ito H. [Experimental study and clinical application of a new combination chemotherapy with cis-platinum, adriamycin and carboquone in patients with advanced prostate cancer]. Nippon Ika Daigaku Zasshi. 1995 Oct;62(5):456-68. Japanese. PubMed PMID: 7499463.

133: Depenbrock H, Wenger M, Peter R, Fellbaum C, Block T, Rastetter J, Hanauske AR. Investigation of the comparative effects of 2-chlorodeoxyadenosine on tumor colony forming units in vitro. Invest New Drugs. 1995;13(2):117-23. PubMed PMID: 8617573.

134: Lévi F. [Chrono-chemotherapy and dose intensity]. Bull Cancer. 1995;82 Suppl 1:29s-36s. French. PubMed PMID: 7626851.

135: Spencer CM, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs. 1994 Nov;48(5):794-847. Review. PubMed PMID: 7530632.

136: Izumi R, Shimizu K, Iyobe T, Ii T, Yagi M, Matsui O, Nonomura A, Miyazaki I. Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology. 1994 Aug;20(2):295-301. PubMed PMID: 8045490.

137: Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci. 1994 Jul;15(7):215-20. Review. PubMed PMID: 7940982.

138: Kirshenbaum MR, Chen SF, Behrens CH, Papp LM, Stafford MM, Sun JH, Behrens DL, Fredericks JR, Polkus ST, Sipple P, et al. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro. Cancer Res. 1994 Apr 15;54(8):2199-206. PubMed PMID: 8174127.

139: Sulkes A, Beller U, Peretz T, Shacter J, Hornreich G, McDaniel C, Winograd B. Taxol: initial Israeli experience with a novel anticancer agent. Isr J Med Sci. 1994 Jan;30(1):70-8. Review. PubMed PMID: 7908013.

140: Bissery MC, Nguyen CH, Bisagni E, Vrignaud P, Lavelle F. Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice. Invest New Drugs. 1993 Nov;11(4):263-77. PubMed PMID: 8157469.

141: Robert J. Epirubicin. Clinical pharmacology and dose-effect relationship. Drugs. 1993;45 Suppl 2:20-30. Review. PubMed PMID: 7693418.

142: Judson IR. The anthrapyrazoles: a new class of compounds with clinical activity in breast cancer. Semin Oncol. 1992 Dec;19(6):687-94. Review. PubMed PMID: 1462167.

143: Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol. 1992 Dec;19(6):670-86. Review. PubMed PMID: 1462166.

144: Matsumoto J, Minami T, Sato T, Onodera T. [A clinical trial of arterial infusion chemotherapy combined with calcium antagonist for liver metastases]. Gan To Kagaku Ryoho. 1992 Aug;19(10 Suppl):1553-6. Japanese. PubMed PMID: 1530306.

145: Ettinger DS, Finkelstein DM, Abeloff MD, Skeel RT, Stott PB, Frontiera MS, Bonomi PD. Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study. J Natl Cancer Inst. 1992 Jul 15;84(14):1077-84. PubMed PMID: 1320131.

146: Okada S, Okazaki N, Nose H, Yoshimori M, Aoki K. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology. 1992 Jul;16(1):112-7. PubMed PMID: 1377657.

147: Graham MA, Workman P. The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: critical evaluation and recommendations for future studies. Ann Oncol. 1992 May;3(5):339-47. Review. PubMed PMID: 1616887.

148: Perno CF, Yarchoan R, Balzarini J, Bergamini A, Milanese G, Pauwels R, De Clercq E, Rocchi G, Calio R. Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages. Antiviral Res. 1992 Apr;17(4):289-304. PubMed PMID: 1322645.

149: Herait P, Poutignat N, Marty M, Bugat R. Early assessment of a new anticancer drug analogue--are the historical comparisons obsolete? The French experience with pirarubicin. Eur J Cancer. 1992;28A(10):1670-6. PubMed PMID: 1389483.

150: Alexander RB. Tumor necrosis factor and chemotherapeutic drugs targeted at DNA topoisomerase II for the treatment of genitourinary malignancies. Cancer Treat Res. 1992;59:105-20. Review. PubMed PMID: 1347688.

151: Loor F, Boesch D, Gavériaux C, Jachez B, Pourtier-Manzanedo A, Emmer G. SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance. Br J Cancer. 1992 Jan;65(1):11-8. PubMed PMID: 1346365; PubMed Central PMCID: PMC1977342.

152: Okada S, Okazaki N. [Chemotherapy in cancers of the gallbladder and bile ducts]. Gan To Kagaku Ryoho. 1991 Jul;18(8):1269-72. Japanese. PubMed PMID: 2069397.

153: Okamoto H, Saijo N. [Preclinical trials from the standpoint of clinical trials]. Gan To Kagaku Ryoho. 1991 Jul;18(9):1467-75. Japanese. PubMed PMID: 1854217.

154: Vescio RA, Connors KM, Kubota T, Hoffman RM. Correlation of histology and drug response of human tumors grown in native-state three-dimensional histoculture and in nude mice. Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5163-6. PubMed PMID: 2052596; PubMed Central PMCID: PMC51832.

155: Dorr RT. Chemoprotectants for cancer chemotherapy. Semin Oncol. 1991 Feb;18(1 Suppl 2):48-58. Review. PubMed PMID: 1899489.

156: Von Roemeling R. The therapeutic index of cytotoxic chemotherapy depends upon circadian drug timing. Ann N Y Acad Sci. 1991;618:292-311. Review. PubMed PMID: 2006791.

157: van Kalken CK, van der Hoeven JJ, de Jong J, Giaccone G, Schuurhuis GJ, Maessen PA, Blokhuis WM, van der Vijgh WJ, Pinedo HM. Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. Eur J Cancer. 1991;27(6):739-44. PubMed PMID: 1829915.

158: Hazama S, Oka M, Shimizu R, Yano K, Yoshino S, Iizuka N, Murakami T, Suzuki T. [Intraarterial combination immunotherapy in hepatocellular carcinoma]. Gan To Kagaku Ryoho. 1990 Aug;17(8 Pt 2):1638-42. Japanese. PubMed PMID: 2167639.

159: Wierzba K, Sugimoto Y, Matsuo K, Toko T, Takeda S, Yamada Y, Tsukagoshi S. Menogaril, an anthracycline compound with a novel mechanism of action: cellular pharmacology. Jpn J Cancer Res. 1990 Aug;81(8):842-9. PubMed PMID: 2144516.

160: Arbuck SG. Overview of chemotherapy for pancreatic cancer. Int J Pancreatol. 1990 Aug-Nov;7(1-3):209-22. Review. PubMed PMID: 2081925.

161: Gianni L, Viganò L, Surbone A, Ballinari D, Casali P, Tarella C, Collins JM, Bonadonna G. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials. J Natl Cancer Inst. 1990 Mar 21;82(6):469-77. PubMed PMID: 2313718.

162: Yamaguchi T, Takahashi T, Yokota T, Kitamura K, Noguchi A, Doi M, Chimori Y, Honda M, Noguchi A, Otsuji E, et al. [Host factors that changes the distribution of immunotoxin]. Gan To Kagaku Ryoho. 1990 Mar;17(3 Pt 2):570-4. Review. Japanese. PubMed PMID: 2138873.

163: Saito R, Tsuchiya S, Ishizuka T, Fueki N, Ezawa K, Minato K, Nakano H, Takise A, Kurihara M, Fueki R. Clinical effects of cepharanthin (Ceph.) on leukopenia by chemotherapy in lung cancer patients. Nippon Gan Chiryo Gakkai Shi. 1989 Dec 20;24(11):2587-93. PubMed PMID: 2559129.

164: Braakhuis BJ, van Dongen GA, Bagnay M, van Walsum M, Snow GB. Preclinical chemotherapy on human head and neck cancer xenografts grown in athymic nude mice. Head Neck. 1989 Nov-Dec;11(6):511-5. PubMed PMID: 2584006.

165: Sothern RB, Lévi F, Haus E, Halberg F, Hrushesky WJ. Control of a murine plasmacytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment. J Natl Cancer Inst. 1989 Jan 18;81(2):135-45. PubMed PMID: 2909754.

166: Noguchi S, Miyauchi K, Nishizawa Y, Sasaki Y, Imaoka S, Iwanaga T, Koyama H, Terasawa T. Augmentation of anticancer effect with angiotensin II in intraarterial infusion chemotherapy for breast carcinoma. Cancer. 1988 Aug 1;62(3):467-73. PubMed PMID: 3292035.

167: Saeki T, Jinushi K, Kodama H, Yoshinaka K, Toge T, Niimoto M, Hattori T. [Fundamental and clinical studies of intra-arterial chemotherapy combined with degradable starch microspheres (DSM)]. Gan To Kagaku Ryoho. 1988 Aug;15(8 Pt 2):2633-9. Japanese. PubMed PMID: 3137886.

168: Tsukagoshi S. [Problems in the development of analogs of anticancer drugs]. Gan To Kagaku Ryoho. 1988 Aug;15(8):2173-8. Japanese. PubMed PMID: 2457354.

169: Speth PA, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet. 1988 Jul;15(1):15-31. Review. PubMed PMID: 3042244.

170: Boven E, Winograd B, Fodstad O, Lobbezoo MW, Pinedo HM. Preclinical phase II studies in human tumor lines: a European multicenter study. Eur J Cancer Clin Oncol. 1988 Mar;24(3):567-73. PubMed PMID: 3383962.

171: Tsukagoshi S. [Introduction of a new anticancer drug, novantrone]. Gan To Kagaku Ryoho. 1987 Nov;14(11):3163-72. Japanese. PubMed PMID: 3314715.

172: Sternberg CN, Sordillo PP, Cheng E, Chuang YJ, Niedzwiecki D. Evaluation of new anticancer agents against human pancreatic carcinomas in nude mice. Am J Clin Oncol. 1987 Jun;10(3):219-21. PubMed PMID: 2884864.

173: Riggs CE Jr, Sharp SA. Adriamycin: review of clinical pharmacology and toxicity of an effective anticancer drug. Iowa Med. 1987 May;77(5):242, 245-51. PubMed PMID: 3298138.

174: Nishiyama M, Nosoh Y, Yamaguchi M, Hirabayashi N, Toge T, Niimoto M, Hattori T. Comparative study on nude mice isotope assay (NM-IA) and subrenal capsule assay (SRCA) sensitivity tests of anticancer agents. Jpn J Surg. 1987 Mar;17(2):99-103. PubMed PMID: 3114529.

175: Robert J. Continuous infusion or intravenous bolus: what is the rationale for doxorubicin administration? Cancer Drug Deliv. 1987;4(3):191-9. Review. PubMed PMID: 3329957.

176: Wadler S, Fuks JZ, Wiernik PH. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds. J Clin Pharmacol. 1986 Sep-Oct;26(7):491-509. Review. PubMed PMID: 2944917.

177: Hagiwara A, Ahn T, Ueda T, Iwamoto A, Ueda T, Torii T, Takahashi T. Anticancer agents adsorbed by activated carbon particles, a new form of dosage enhancing efficacy on lymphnodal metastases. Anticancer Res. 1986 Sep-Oct;6(5):1005-8. PubMed PMID: 2432828.

178: Collins JM, Zaharko DS, Dedrick RL, Chabner BA. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep. 1986 Jan;70(1):73-80. PubMed PMID: 3753662.

179: Neri B, Cini-Neri G. Inhibition of endogenous respiration in rat heart slices as a measure of mitoxantrone cardiac toxicity. Oncology. 1986;43(4):264-7. PubMed PMID: 3725288.

180: Hurteloup P, Ganzina F. Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin. Drugs Exp Clin Res. 1986;12(1-3):233-46. Review. PubMed PMID: 3525075.

181: Morris GL, Zeltzer PM, Schneider SL, Von Hoff DD. Cloning of pediatric malignancies for drug sensitivity testing in the human tumor cloning assay. Am J Pediatr Hematol Oncol. 1986 Spring;8(1):52-7. PubMed PMID: 3013039.

182: Romanini A, Febi G, Danesi R, Del Tacca M. [Recent pharmacotoxicologic and clinical findings on adriamycin]. Minerva Med. 1985 Oct 20;76(40):1863-76. Review. Italian. PubMed PMID: 2997664.

183: Hrushesky WJ. Circadian timing of cancer chemotherapy. Science. 1985 Apr 5;228(4695):73-5. PubMed PMID: 3883493.

184: Yoshimori M, Tajiri H, Nakamura K, Ozaki H. [Chemotherapy of pancreatic cancer]. Gan To Kagaku Ryoho. 1985 Feb;12(2):227-34. Japanese. PubMed PMID: 3155930.

185: Schlag P, Flentje D. Chemosensitivity testing of human neoplasms using the soft agar colony assay. Cancer Treat Rev. 1984 Mar;11 Suppl A:131-7. PubMed PMID: 6733715.

186: Reich SD. Rationale for anticancer drug dosing schedules. Cancer Nurs. 1983 Dec;6(6):465-7. PubMed PMID: 6360342.

187: Carlson RW, Sikic BI. Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med. 1983 Dec;99(6):823-33. Review. PubMed PMID: 6197002.

188: Giovanella BC, Stehlin JS Jr, Shepard RC, Williams LJ Jr. Correlation between response to chemotherapy of human tumors in patients and in nude mice. Cancer. 1983 Oct 1;52(7):1146-52. PubMed PMID: 6883283.

189: Schabel FM Jr, Skipper HE, Trader MW, Laster WR Jr, Griswold DP Jr, Corbett TH. Establishment of cross-resistance profiles for new agents. Cancer Treat Rep. 1983 Oct;67(10):905-22. Review. PubMed PMID: 6354439.

190: Hahn DA. Hexamethylmelamine and pentamethylmelamine: an update. Drug Intell Clin Pharm. 1983 Jun;17(6):418-24. PubMed PMID: 6407810.

191: Garattini S. Is it necessary to measure plasma levels of anticancer drugs? Biomed Pharmacother. 1983;37(5):209-10. PubMed PMID: 6661506.

192: Neidhart JA, Gagen M, Young D, Wilson HE. Specific antiemetics for specific cancer chemotherapeutic agents: haloperidol versus benzquinamide. Cancer. 1981 Mar 15;47(6):1439-43. PubMed PMID: 7013968.

193: Zimmerman SE, Smith FP, Schein PS. Chemotherapy of pancreatic carcinoma. Cancer. 1981 Mar 15;47(6 Suppl):1724-8. PubMed PMID: 6456058.

194: Chauvergne J, Durand M, Berlie J. [The chemotherapy of advanced breast cancer. A report on the first 600 cases in a cooperative programme to carry out a systematic study (1974-1977) (author's transl)]. J Gynecol Obstet Biol Reprod (Paris). 1978 May-Jun;7(4):877-86. French. PubMed PMID: 361799.

195: Weiss AJ, Manthel RW. Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity. Cancer. 1977 Nov;40(5):2046-52. PubMed PMID: 336177.